Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1Phase 1 1

Status

Terminated 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4Breast 3Thoracic 2Gynecologic 1

Conditions

Breast Neoplasms 34Colorectal Neoplasms 8Brain Neoplasms 8Neoplasms 5HER2-positive Breast Cancer 5Stomach Neoplasms 4Neoplasm Metastasis 4Carcinoma, Non-Small-Cell Lung 4Triple Negative Breast Neoplasms 3Meningeal Neoplasms 3Rectal Neoplasms 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Colonic Neoplasms 2Adenocarcinoma Of Esophagus 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Pathologic Complete Response 1Ovarian Neoplasms 1Neoplasms by Site 1Metastatic Breast Cancer With a Isolated Brain Progression 1Meningeal Carcinomatosis 1Lung Neoplasms 1Hemangiosarcoma 1HER2-positive Metastatic Breast Cancer 1HER2-positive Gastric Cancer 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Cholangiocarcinoma 1

Interventions

Oxaliplatin 295Capecitabine 209Fluorouracil 183Cisplatin 172Docetaxel 140S 1 (combination) 135Paclitaxel 128Leucovorin 117Irinotecan 110pembrolizumab 104Trastuzumab 75Nivolumab 59apatinib 57Drug Therapy 52sintilimab 46Surgical Procedures, Operative 45Ramucirumab 40Radiotherapy 40Bevacizumab 37Hyperthermic Intraperitoneal Chemotherapy 34Epirubicin 32titanium silicide 31tislelizumab 31Carboplatin 31Gastrectomy 28Cyclophosphamide 27XELOX 25Tegafur 24Folfox protocol 23Albumin-Bound Paclitaxel 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Stomach Neoplasms × tucatinib × Clear all
NCT06157892 2026-05-05

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Seagen Inc.

Phase 2 Recruiting
172 enrolled
BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT04430738 2026-02-24

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Seagen Inc.

Phase 2 Active not recruiting
40 enrolled 67 charts
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Gallbladder Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT02892123 2024-11-27

Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

Jazz Pharmaceuticals

Phase 1 Completed
279 enrolled
BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT05091528 2022-08-18

A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers

Silverback Therapeutics

Phase 1/2 Terminated
2 enrolled 9 charts
BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡